Ginkgo grows its gene therapy offerings with StrideBio deal
Bio Pharma Dive
APRIL 5, 2023
The deal hands Ginkgo technology for discovering and engineering capsids — the outer shell that protects the helpful genetic material in gene therapies.
Engineer Gene Genetics 
Experiment Reveals Human Genes Can Be Controlled With Electricity
AuroBlog - Aurous Healthcare Clinical Trials blog
AUGUST 7, 2023
New research from ETH Zürich in Switzerland could see future wearable devices (with perhaps a few implants and a touch of genetic engineering) boost our health directly. Fitness trackers help you stay healthy by keeping count of your steps and monitoring your heart rate, driving you on to hit those cardio goals.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Capsida Biotherapeutics and Prevail to develop CNS gene therapies
Pharmaceutical Technology
JANUARY 5, 2023
Capsida Biotherapeutics and Eli Lilly and Company ’s wholly owned subsidiary Prevail Therapeutics have announced a partnership for the development of non-invasive gene therapies for central nervous system (CNS) diseases. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. By Cytiva Thematic.
Gene Therapy 
237
237 
ElevateBio raises funds to advance cell and gene therapies
Pharmaceutical Technology
MAY 25, 2023
ElevateBio has raised $401m in a Series D financing round for advancing its technology platforms to expedite the design, production and development of cell and gene therapies. The technology platforms include the Life Edit gene editing platform, an RNA, cell, protein, vector engineering and induced pluripotent stem cells (iPSCs) platform.
Gene Therapy 243
243 
Biologists create new genetic systems to neutralize gene drives
Scienmag
SEPTEMBER 18, 2020
Two active genetics strategies help address concerns about gene-drive releases into the wild Credit: Ana Silva In the past decade, researchers have engineered an array of new tools that control the balance of genetic inheritance.
Genetics 86
86 
Ginkgo buys StrideBio’s AAV discovery and engineering platform assets
Pharmaceutical Technology
APRIL 6, 2023
Ginkgo Bioworks has strengthened its end-to-end R&D capabilities in gene therapy with the purchase of adeno-associated virus (AAV) capsid discovery and engineering assets from StrideBio, for an undisclosed sum. The new capabilities and IP will be incorporated under Ginkgo’s end-to-end AAV gene therapy development platform.
Engineer 130
130 
Asklepios partners with ReCode on gene-editing platform
Pharmaceutical Technology
JANUARY 10, 2023
Asklepios BioPharmaceutical has entered a research partnership and option agreement with ReCode Therapeutics for exploring its single-vector gene-editing platform. The new solution will enable complete gene insertion by delivering the gene-editing tool and DNA as mixed cargo to desired targets in one LNP. By Cytiva Thematic.
Gene Editing 130
130 
Scribe and Prevail partner for CRISPR-based genetic medicines
Pharmaceutical Technology
MAY 17, 2023
The deal will see the integration of Scribe’s new CRISPR by Design approach and Prevail’s expertise in developing genetic medicines for neurological disorders for specific genetic targets. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Genetics 130
130 
CRISPR Pioneer Goes Small to Transform Genetic Medicine with Epigenetic Engineering
BioSpace
JULY 11, 2022
Epic Bio aims to transform genetic medicine by developing a new class of drugs that target the epigenome to alter gene expression.
Genetics 81
81 
Moderna partners with Life Edit for mRNA gene editing therapies
Pharmaceutical Technology
FEBRUARY 23, 2023
Moderna has entered a strategic research and development partnership with ElevateBio’s Life Edit Therapeutics to discover and develop new in-vivo mRNA gene editing therapies. Our novel editing systems have the potential to precisely modify gene targets for both in vivo and ex vivo therapeutic development.”
Gene Editing 147
147 
AbbVie and Capsida partner for gene therapies to treat eye diseases
Pharmaceutical Technology
FEBRUARY 24, 2023
AbbVie is expanding its strategic collaboration with Capsida Biotherapeutics for the development of targeted genetic medicines to treat eye diseases with high unmet needs. In pursuing the promise of genetic medicine-based therapeutics, AbbVie continues to expand our capabilities, and we are pleased to have Capsida as a partner.”
Gene Therapy 130
130 
Synthetic SPECIES developed for use as a confinable gene drive
Scienmag
JUNE 2, 2021
Researchers create novel CRISPR-based fly species as a new method of controlling gene drive spread Credit: Akbari lab, UC San Diego CRISPR-based technologies offer enormous potential to benefit human health and safety, from disease eradication to fortified food supplies.
Gene 98
98 
STAT+: CRISPR patent fight redux? A new battle is brewing among biotechs over next-gen gene-editing tools
STAT News
MARCH 1, 2023
Genome editing summits are generally friendly, nerdy affairs, but for a moment at a Lisbon hotel last June, the conversation at the FASEB genome engineering conference grew tense. ” It was a rare moment: Tessera had raised around $600 million and passed a $1 billion valuation, but published little in academic medical journals.
Gene Editing 119
119 
Biogen’s ambitions in gene therapy hit by another failed pivotal trial
pharmaphorum
JUNE 15, 2021
When Biogen acquired Nightstar Therapeutics in 2019, it added a pair inherited retinal disorder (IRD) gene therapies that it hoped would accelerate a push into the fast-evolving category. . The post Biogen’s ambitions in gene therapy hit by another failed pivotal trial appeared first on.
Gene Therapy 105
105 
Mapping Networks of Immune Genes Behind Autoimmune Diseases
XTalks
JULY 14, 2022
Every gene in a cell is expressed at exact levels due to complex gene regulatory networks. The connections between regulatory genes and their downstream targets have been mapped to some extent — they can be thought of as a subway or metro map, with connections existing between major “hubs.”
Gene 98
98 
Enabling the next wave of innovative drug therapies with speciality enzymes
Pharmaceutical Technology
JUNE 29, 2022
The next wave of medicine is well on course to be cell and gene-based. For cell and gene therapy applications, you need a variety of speciality enzymes of the highest purity, specificity, and consistency. Novozymes has a long legacy of enzyme discovery and the ability to genetically engineer these speciality enzymes to be superior.
Drugs 295
295 
Pfizer’s haemophilia B gene therapy meets phase 3 primary endpoint
pharmaphorum
JANUARY 3, 2023
As December 2022 closed out, Pfizer announced positive top-line results from its phase 3 BENEGENE-2 study evaluating fidanacogene elaparvovec (SPK-9001), its investigational gene therapy for treatment of adult males with moderately severe to severe haemophilia B.
Gene Therapy 98
98 
Combining genetic information with EMRs to pinpoint childhood epilepsies
Scienmag
AUGUST 11, 2020
Assessing clinical data across the lifespan identified the impact of genetic epilepsies on affected children’s lives Philadelphia, August 11, 2020 – A team of researchers at Children’s Hospital of Philadelphia (CHOP) affiliated with the CHOP Epilepsy Neurogenetics Initiative (ENGIN) further bridged the gap between genomic information (..)
Genetics 70
70 
IBC vs. IRB: What’s the Difference?
Advarra
JUNE 12, 2023
Gene therapy research is exciting and full of promise, but because of the risks involved, it’s also highly regulated, requiring an institutional biosafety committee (IBC) to provide additional oversight and risk assessment. What Does an IBC Review? How is IBC Membership Composed?
STAT+: Pharmalittle: FDA approves a gene therapy for a rare blood disorder; pharmacy chains ordered to pay $650 million over opioid crisis
STAT News
AUGUST 18, 2022
Food and Drug Administration approved a new treatment that delivers a potentially permanent, genetic fix for patients with the inherited blood disorder beta thalassemia — and quite possibly a financial lifeline for its manufacturer, Bluebird Bio , STAT tells us. Zynteglo will cost $2.8 Continue to STAT+ to read the full story…
Gene Therapy 98
98 
Cancer immunotherapy approach targets common genetic alteration
Scienmag
MARCH 15, 2021
Engineered T cells can recognize and destroy cells with loss of one gene copy Credit: Elizabeth Cook Researchers developed a prototype for a new cancer immunotherapy that uses engineered T cells to target a genetic alteration common among all cancers.
Genetics 54
54 
Genetic eraser: Newly developed technology precisely and rapidly degrades targeted proteins
Scienmag
NOVEMBER 11, 2020
“Conditional gene knockout and small interfering RNA […]. Credit: Masato Kanemaki Researchers can now more accurately and precisely target specific proteins in yeast, mammalian cells and mice to study how knocking down specific protein traits can influence physical manifestation in a cell or organism.
Protein 98
98 
#news #biotech Genetic engineering without unwanted side effects helps fight parasites
BioTech 365
DECEMBER 23, 2020
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Genetic engineering without unwanted side effects helps fight parasites.Modified CRISPR-Cas9 gene editing scissors are enabling researchers at the University of Zurich to make alterations to the genetic … Continue reading (..)
Opinion: Where are the guidelines for the production of animals with intentional genomic alterations?
STAT News
APRIL 17, 2023
Genetic engineering has the potential to transform how we raise animals for meat and other products, making food safer, improving animal health and welfare, and shrinking animal agriculture’s environmental footprint. Pigs that are less likely to induce allergic reactions in humans.
Genomics 98
98 
New ‘split-drive’ system puts scientists in the (gene) driver seat
Scienmag
MARCH 5, 2021
Researchers develop tunable system that harnesses the spread of cargo carried by gene drives Credit: Gerard Terradas, UC San Diego Powerful new genetic engineering methods have given scientists the potential to revolutionize several sectors of global urgency.
Gene 52
52 
Singapore scientists develop novel gene editor to correct disease-causing mutations
Scienmag
MARCH 11, 2021
The CRISPR-based gene editor, C-to-G Base Editor (CGBE), opens up treatment avenues for up to 40 per cent of genetic disorders caused by single-nucleotide mutations Credit: Agency for Science, Technology and Research (A*STAR), Genome Institute of Singapore (GIS) A team of researchers from the Agency for Science, Technology and Research’s (A*STAR) (..)
Gene 74
74 
Sonoma signs deal to set up manufacturing centre for cell therapies
Pharmaceutical Technology
AUGUST 25, 2022
The centre, which will expand the company’s operations in Seattle, US, will aid in the R&D and manufacturing at scale its gene-modified regulatory T cell (T reg ) therapy pipeline for autoimmune and inflammatory ailments. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Manufacturing 130
130 
Generating Over a Billion Cells with CRISPR for Next Generation Cell Therapies
XTalks
AUGUST 29, 2022
Now a common gene editing tool, the popularity of the CRISPR-Cas9 system has increased over the past decade. CRISPR is notable for engineering living cells, allowing scientists to edit, turn off, delete, or replace genes in a cell’s genome. Harnessing the Cellular Engineering Potential of CRISPR.
Gene Editing 98
98 
#news #biotech Biologists create new genetic systems to neutralize gene drives
BioTech 365
SEPTEMBER 18, 2020
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Biologists create new genetic systems to neutralize gene drives.In the past decade, researchers have engineered an array of new tools that control the balance of genetic inheritance.
Genetics 40
40 
Ctexli (Chenodiol) Gains FDA Approval as First CTX Treatment
XTalks
FEBRUARY 25, 2025
CTX is a rare, progressive genetic disorder caused by mutations in the CYP27A1 gene, which disrupts the livers ability to produce chenodeoxycholic acid, a bile acid. Preclinical studies in a CTX mouse model demonstrated that VTX806 normalizes toxic bile acid metabolite levels in the blood, liver, tendons and brain.
FDA Approval 59
59 
Scribe and Sanofi partner to develop cell therapies for cancer
Pharmaceutical Technology
SEPTEMBER 29, 2022
The alliance will leverage the CRISPR genome editing technologies of Scribe to facilitate in genetic modification of new natural killer (NK) cell therapeutics for cancer. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. According to the deal, Sanofi will make an upfront payment of $25m to Scribe.
Development 130
130 
AstraZeneca pays record 660% premium for gene editing company LogicBio
pharmaphorum
OCTOBER 4, 2022
AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 million. The post AstraZeneca pays record 660% premium for gene editing company LogicBio appeared first on.
Gene Editing 64
64 
Molecule holds promise to reprogram white blood cells for better cancer treatment
Scienmag
DECEMBER 13, 2020
In this type of therapy, T cells, a type of white blood cell, are collected from a patient’s blood and subjected to genetic engineering to produce T cells carrying a synthetic molecule termed chimeric antigen receptor (CAR) […].
Biogen Pushes Deeper into Gene Therapy with Capsigen Collaboration
BioSpace
MAY 10, 2021
Biogen and Capsigen forged a strategic collaboration to engineer novel adeno-associated virus (AAV) capsids that have the potential to become transformative gene therapies that treat underlying genetic causes of various central nervous system and neuromuscular disorders.
Gene Therapy 52
52 
The convergence of epigenetics and math to predict and intercept cancer cell behavior
Medical Xpress
FEBRUARY 10, 2023
It is now widely understood that cancer is a disease of acquired defects in genes and gene function. of the Yale School of Engineering and Applied Science, addresses new quantitative approaches to better define and measure these defects in gene function, known as epigenetics, and their interplay with the genetic landscape of cancer.
Gene 75
75 
Genetically engineered T cells could lead to therapies for autoimmune diseases
Scienmag
DECEMBER 3, 2020
A new study has found that a novel T cell genetically engineered by University of Arizona Health Sciences researchers is able to target and attack pathogenic T cells that cause Type 1 diabetes, which could lead to new immunotherapy treatments.
How Centralized IBC Review Can Benefit Gene Therapy Research
Advarra
AUGUST 8, 2023
Gene therapy research is booming in the clinical setting. In this blog, we summarize the growth, risks, and regulatory requirements for gene therapy research. Defining the Boom in Gene Therapy Research The gene therapy field is experiencing explosive growth in today’s competitive research environment.
Gene Therapy 52
52 
Scientists use DNA origami to monitor CRISPR gene targeting
Scienmag
FEBRUARY 23, 2021
CRISPR gene editing has transformed research, but it is not perfect, and can sometimes target unintended genes; to watch CRISPR enzymes respond to different genes, Leipzig University researchers developed a new method using DNA origami and were able to me Credit: Image courtesy of Julene Madariaga Marcos.
DNA 56
56 
The Equalizer: An engineered circuit for uniform gene expression
Scienmag
JULY 12, 2021
The function of a protein can depend on its abundance in a cell. So, when investigating the properties of a new protein, it is essential to make sure that the same amount is produced by every cell. Researchers at Baylor College of Medicine and Rice University have found a new way to do just that […].
New genetic analysis method could advance personal genomics
Scienmag
SEPTEMBER 10, 2020
Computational method capable of decoding influence of rare variants Geneticists could identify the causes of disorders that currently go undiagnosed if standard practices for collecting individual genetic information were expanded to capture more variants that researchers can now decipher, concludes new Johns Hopkins University research.
Gene therapy using ‘zinc fingers’ may help treat Alzheimer’s disease, animal study shows
Scienmag
MARCH 19, 2021
Treatment involving a single injection has long-lasting effects BOSTON – Researchers have used a genetic engineering strategy to dramatically reduce levels of tau–a key protein that accumulates and becomes tangled in the brain during the development of Alzheimer’s disease–in an animal model of the condition.
Gene Therapy 66
66 
Rare inherited variants in previously unsuspected genes may confer significant risk for autism
Scienmag
JULY 26, 2021
New Study in Nature Genetics uses SPARK database to investigate variants that are less damaging than de novo mutations, but contribute almost as much risk New York, NY (July 26, 2021) – Researchers have identified a rare class of genetic differences transmitted from parents without autism to their affected children with autism and determined (..)
Genetics 75
75 
Q&A: A decade on, what’s next for CAR-T therapies?
Pharmaceutical Technology
APRIL 5, 2023
More broadly however, several advancements are on the horizon for cell and gene therapies in 2023. This includes the first potential approval of a CRISPR-based gene therapy called exa-cel , which is developed by CRISPR Therapeutics and Vertex Pharmaceuticals. AZ: Cell and gene therapies often come with a high price.
Gene Therapy 147
147 
World Cancer Day 2024: Trends in Oncology Research and More
XTalks
JANUARY 26, 2024
Innovations in Cancer Therapy CRISPR/Cas9, a groundbreaking gene-editing technology, has demonstrated significant potential in oncology, offering new avenues for cancer treatment. By editing these genes, researchers can effectively neutralize their cancer-promoting effects.
Research 118
118 
Let's personalize your content